The results of a radionuclide skeletal survey were comparatively assessed in 30 patients with breast cancer 6 months to 3 years after completion of combination treatment. A primary survey was conducted using Tc-99m pyrophosphate; a resurvey applied Tc-99m resoscan. X-ray computed tomography was employed to verify the nature of bone changes in questionable cases. Osteoscintigraphy with the new radiopharmaceutical Tc-99m resoscan was ascertained to increase the number of detectable metastases by 16.7% due to the fact that pathological osteolytic foci may be visualized, as compared to the conventional survey with labeled pyrophosphates. The use of a procedure for virtually reducing the injected radiolabel activity decreased radiation load per patient by 25%, without worsening the quality of obtained scans.